TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Health-related Quality of Life (HrQol)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total acquisition time (both eyes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in line managers confidence to create a mentally healthy workplace
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of miRNA in sweat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of miRNA in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL-severe)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the concentration of urinary cannabinoid metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Client FAST Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Depressive levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion of guideline-recommended surveillance tests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients With Successful Bowel Cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IGA score for patients with melasma or post-acne post-inflammatory hyperpigmentation (PIHP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: modified Melasma Area Severity Index (mMASI) for patients with melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-Acne Hyper Pigmentation Index (PAHPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: solar lentigo pigmentation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of additional Barrett's neoplasia found
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lipids profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: type and frequency of device-related and procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Visuai Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Handgrip Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Papillary height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of peri-implant mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analog Scale Change
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Balance recovery outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe hypoglycaemic events detection
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoglycaemic events detection
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperglycaemic events detection
Endpoint domain: Adverse events/effects
Primary endpoint: Severe hyperglycaemic events detection
Endpoint domain: Adverse events/effects
Primary endpoint: Risk awareness in women
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ability to collect complete data for patient-reported outcomes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Flying Kick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whirlwind Kick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of MDMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency (%) of swallows initiated during expiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Penetration-Aspiration Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of potentially fatal rhythmic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viscoelastic properties of thoracolumbar fascia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychotic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinical Global Impression (CGI) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cutaneous microvascular responses to local heating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated dilation responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitochondrial ROS production in peripheral blood mononuclear cells (PBMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events (AE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related adverse events (TRAE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of variants in the GBA/PSAP genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Complete Response Rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Residual Disease (MRD) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline State Test Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Facial morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRS 0-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COMPASS-31 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Functional Disability Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: heart rate increase in head up tilt table tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of interstitial syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in impulsivity level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in eating attitude
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in eating behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue induced craving for methamphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-directed learning ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: hair regrowth improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary site CR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Set A Target Quit Date (TQD)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Complete Phone Counseling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adverse Airway Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Development of post-traumatic acute endophthalmitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiorespiratory health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HPV 16/18 E6E7 specific immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and specificity of test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of wound dehiscence or other wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: Hematoma vacuum assisted biopsy success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Resolution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in health behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of VRVF compared to SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of VRVF compared to SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in mean rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in hsCRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to Immunosuppressive Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of SCD, stroke, or hospitalization/intervention/ED visit due to arrhythmias
Endpoint domain: Mortality/survival
Primary endpoint: Sleep Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of aerobic capacity from baseline to post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of anaerobic capacity from baseline to post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of muscular strength from baseline to post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of knee joint moments from baseline to post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Level of sports nutrition knowledge of high school athletes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of sports nutrition knowledge of influencers of high school athletes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: hypophosphatemia occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Post prandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Post prandial blood HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positional Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute phase safety
Endpoint domain: Adverse events/effects
Primary endpoint: Change in non motor symptoms scale from baseline to 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Visual Analog Pain (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain severity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and Function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and duration of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in family communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in treatment facilitation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in treatment engagement, general
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in treatment engagement, specialty
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Black cis women initiating HIV PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical regression of dysplastic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First running-related injury
Endpoint domain: Adverse events/effects
Primary endpoint: Capability of patients to use SRAVI as a communication aid
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability of SRAVI as a communication aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: metastatic lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional disability at 2 hours post-treatment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improve of quality of life assessed by PedsMIDAS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of NOP-LBBB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of discontinuation due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Caries experiences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: qEEG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time to epithelial healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline stratum corneum hydratation (SCH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline Skin surface pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline Transepidermal water loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of local and/or systemic occurrence of infection on the PICCline
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in liver aminotransferases (ALT and AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: NAFLD fibrosis score (NFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Efficacy of the combination treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants with Reactogenicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with MAAEs, NCIs, and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of extrinsic compression of the LMCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of adverse reactions/events within 30 minutes after each dose of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of SAE from the first dose of vaccination to 6 months after the full course of vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aided audiometric threshold testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aided speech-in-noise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin Bone/Tissue Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic Vancomycin Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Ventilator-Free Days (VFD) by Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Blood Sugar Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acne vulgaris severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAM-D-17 Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QIDS SR-16 Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthetic Limb User's Survey of Mobility (PLUS-M)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Long-term Neurodevelopment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sprint test (0-30m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yo-Yo Intermittent endurance test level I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor necrosis factor (TNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon gamma (IFN-γ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vascular cell adhesion protein 1 (VCAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance changes on cognitive tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Elasticity of the supraspinatus tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in markers of systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in markers of neuronal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of conventional markers of HE and clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amygdala-to-cerebellum ratio of glycolytic metabolic activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between the rest and stress amygdala-to-cerebellum perfusion ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial flow reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of gall bladder stones
Endpoint domain: Adverse events/effects
Primary endpoint: Core body temperature changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardio-vascular evaluations changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep scoring changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 Hour Interstitial Glucose Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of non-rapid eye movement sleep stage 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Full Mouth Plaque Score (FMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Pain during and after administration of atosiban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale (NRS) of Current Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk factors associated with esophageal squamous cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median local progression free survival (lPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Radiation-related acute neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Radiation-related late neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Problem Areas in Diabetes (PAID)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Structural Racial Discrimination Index (SRD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to next treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ketone Bodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of AEs, SAEs, and abnormalities in Lab
Endpoint domain: Adverse events/effects
Primary endpoint: safety rate
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes